Search Results | Blood | American Society of Hematology

1-20 of 845

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

DOI: https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Alexey Danilov, MD PhD, Habte A Yimer, MD, Michael Boxer, MD, John M Burke, MD, Sunil Babu, MD, Jia Li, PhD, Yong Mun, PhD, Peter C Trask, PhD MPH, Anthony S Masaquel, PhD MPH, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 3491.

DOI: https://doi.org/10.1182/blood-2019-123630

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

DOI: https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

DOI: https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

DOI: https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

John D Belcher, PhD, Margaret Biddle, PhD, Domi Stickens, PhD, Lyndsay Olson, Eric Bell, Chunsheng Chen, Fuad Abdulla, Julia Nguyen, Zachary Monroe Kiser, BS, PhD, Jacob Lloyd, MD, Gregory M Vercellotti, MD

Blood (2019) 134 (Supplement_1): 983.

DOI: https://doi.org/10.1182/blood-2019-127300

Published: 2019

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

DOI: https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

DOI: https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

DOI: https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Ben Buelow, MD PhD, Anita D'Souza, MBBS, Cesar Rodriguez, MD, Ravi Vij, MBBS, Rajneesh Nath, MD, Melinda Snyder, MS, Duy Pham, MBA, Ashwin Patel, PhD, Suhasini Iyer, PhD

Blood (2019) 134 (Supplement_1): 1874.

DOI: https://doi.org/10.1182/blood-2019-123220

Published: 2019

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

DOI: https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

Clearance of Vector DNA Following Systemic Administration of AAV5-hFIX or AAV5-hFIX Padua in Patients with Severe or Moderate-Severe Hemophilia B

Eileen K Sawyer, PhD, Sander Gielen, PhD, Jaap Twisk, Alison Long, Robert Gut

Blood (2019) 134 (Supplement_1): 2062.

DOI: https://doi.org/10.1182/blood-2019-129786

Published: 2019

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS

Blood (2019) 134 (Supplement_1): 1864.

DOI: https://doi.org/10.1182/blood-2019-131806

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

DOI: https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Fred Schiffman, MD, Cynthia S Peng, BS, Anna C Delamerced, BA, Lauren V Ready, MPH, Kevin S Tang, BA, Pamela Yan, BS, Laura L Butterfield, BSN, Alexandra Krupa, RN BSN ACM

Blood (2019) 134 (Supplement_1): 2187.

DOI: https://doi.org/10.1182/blood-2019-125265

Published: 2019

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

DOI: https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 1299.

DOI: https://doi.org/10.1182/blood-2019-130283

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

DOI: https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

DOI: https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

DOI: https://doi.org/10.1182/blood-2019-131014

Published: 2019

2 3 4 5

NARROW

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Clearance of Vector DNA Following Systemic Administration of AAV5-hFIX or AAV5-hFIX Padua in Patients with Severe or Moderate-Severe Hemophilia B

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only